Myriad Genetics Company Profile

09:27 EST 11th December 2018 | BioPortfolio

Myriad Genetics, Inc. is a leader in the discovery of major common human disease genes and their related pathways. TheCompany utilizes analyses of extensive family histories and genetic material, as well as a number of proprietary technologies, to identify inherited gene mutations which increase the risk to individuals of developing these diseases.

The Company has also developed ProNet(TM), a proprietary high-throughput assay to identify protein-protein interactions. The Company believes that the application of these technologies may provide new insights into protein function and cellular organization which may lead to the identification of novel therapeutic targets. The discovery of disease-predisposing genes and their biochemical pathways provides the Company with three significant commercial opportunities: (i) the development and marketing of genetic testing and information services, such as its BRACAnalysis(TM) test and its recently launched CardiaRisk(TM) test, for the identification of individuals who are genetically predisposed to developing a particular disease, (ii) the marketing of subscriptions to the ProNet(TM) database of protein interactions, and (iii) the development of therapeutic products for the treatment and prevention of major diseases associated with these genes and their biochemical pathways.


320 Wakara Way
Salt Lake City
United States of America


Phone: 801 584 3600
Fax: 801 584 3640

News Articles [448 Associated News Articles listed on BioPortfolio]

Myriad Genetics, Pfizer team up in companion Dx deal

Myriad Genetics Inc. and Pfizer Inc. are teaming up to commercialize Myriad’s BRACAnalysis CDx as a companion diagnostic with the Big Pharma’s breast cancer drug talazoparib.

Myriad Genetics Signs Definitive Agreement to Acquire Counsyl

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier...

Counsyl to be acquired by Myriad Genetics in $375M deal

A deal has been reached by Myriad Genetics to pay about $375 million for genetic testing and DNA analysis services provider C -More- 

Myriad Signs Commercialization Plan With Pfizer

NEW YORK CITY (dpa-AFX) - Myriad Genetics, Inc. (MYGN) announced that it has signed a commercialization plan with Pfizer Inc. under an existing companion diagnostic agreement, in which Myriad is p...

Myriad Genetics acquires reproductive testing firm Counsyl for $375mm in cash and stock

Myriad Genetics Inc. agreed to acquire privately held Counsyl Inc., a DNA screening company focused on prenatal testing, women's health, and hereditary disorders.

Myriad Genetics to acquire health technology company, Counsyl for $375 million

Myriad Genetics, Inc., a leader in molecular diagnostics and personalised medicine, has signed a definitive agreement to acquire Counsyl, a pioneer in expanded carrier screening and non─invasive pre...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed Against Myriad Genetics, Inc. - MYGN

RADNOR, PA / ACCESSWIRE / May 29, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Myriad Genetics, Inc. (NASDAQ: MYGN) ("Myriad") investors that a class action lawsuit has been fi...

Myriad Genetics, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 15102018] Prices from USD $175

Myriad Genetics, Inc. Strategy, SWOT and Corporate Finance ReportSummaryMyriad Genetics, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. ...

Drugs and Medications [0 Results]


PubMed Articles [627 Associated PubMed Articles listed on BioPortfolio]

Genetics is the logic of life (at least of mine).

I retrace my path from math to medicine to biochemistry to yeast genetics, my focus on infectious diseases of yeast and finally prions. My discovery of yeast prions relied on my particular focus on th...

Response to Nakaguma et al.

Correction: Moss genetics and the way forward.

[This corrects the article DOI: 10.1371/journal.pgen.1007330.].

Genome-first findings require precision phenotyping.

Big data phenotyping in rare diseases: some ethical issues.

Clinical Trials [359 Associated Clinical Trials listed on BioPortfolio]

Genetics Education: Preparing Physicians for the Future

This study examines the best way to teach genetics to family medicine residents. First year family medicine residents at the University of Toronto will be taught basic clinical genetics as...

Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics

This study will describe the experience of patients with visible physical abnormalities in the genetics clinic when they are involved in teaching others about their condition. Information ...

Virtual Reality Intervention in Cancer Genetics

The goal of this study is to evaluate a virtual reality-based intervention for training health care providers who are not genetics specialists to effectively communicate with and counsel p...

Genetics Tests : How to Improve Management Within Two Medical Specialities

This survey will assess discrepancies between official clinical genetics guidelines and practices within 3 West regions of France.

Genetics of Asthma and Bronchial Hyperresponsiveness

To investigate the genetics of asthma by reexamining a carefully characterized population of patients with asthma, and by studying their families.

Companies [63 Associated Companies listed on BioPortfolio]

Myriad Genetics, Inc.

Myriad Genetics, Inc. is a biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products. Myriad's news and other information are available on t...

Myriad House

PR Week ranks Myriad as a UK top 150 PR agency and as number one in Cambridgeshire and across the East of England region. One of the country’s leading healthcare agencies, and among the largest...

AccessDNA, Inc.

AccessDNA is the leading online consumer resource for genetics. The company combines high-quality content about genetics with access to, and evaluation of, relevant testing, couns...

Ambry Genetics Corporation

Ambry Genetics is a privately held healthcare company with the industry’s most comprehensive suite of genetic testing solutions, benefiting 90% of all U.S. patients covered b...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent ce...

More Information about "Myriad Genetics" on BioPortfolio

We have published hundreds of Myriad Genetics news stories on BioPortfolio along with dozens of Myriad Genetics Clinical Trials and PubMed Articles about Myriad Genetics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Myriad Genetics Companies in our database. You can also find out about relevant Myriad Genetics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Corporate Database Quicklinks

Searches Linking to this Company Record